During the last session, Gyre Therapeutics Inc (NASDAQ:GYRE)’s traded shares were 0.1 million, with the beta value of the company hitting 1.81. At the end of the trading day, the stock’s price was $8.88, reflecting an intraday gain of 11.84% or $0.94. The 52-week high for the GYRE share is $19.00, that puts it down -113.96 from that peak though still a striking 31.19% gain since the share price plummeted to a 52-week low of $6.11. The company’s market capitalization is $766.63M, and the average intraday trading volume over the past 10 days was 0.16 million shares, and the average trade volume was 139.62K shares over the past three months.
Gyre Therapeutics Inc (NASDAQ:GYRE) trade information
Gyre Therapeutics Inc (GYRE) registered a 11.84% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 11.84% in intraday trading to $8.88, hitting a weekly high. The stock’s 5-day price performance is 21.81%, and it has moved by -13.62% in 30 days. Based on these gigs, the overall price performance for the year is -44.50%. The short interest in Gyre Therapeutics Inc (NASDAQ:GYRE) is 2.39 million shares and it means that shorts have 11.25 day(s) to cover.
Gyre Therapeutics Inc (GYRE) estimates and forecasts
In the rating firms’ projections, revenue will increase 19.61% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 28.4M as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 28.7M by the end of current fiscal year.
While earnings are projected to return 140.00% in 2025.
GYRE Dividends
Gyre Therapeutics Inc is due to release its next quarterly earnings on 2025-Mar-16. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Gyre Therapeutics Inc (NASDAQ:GYRE)’s Major holders
Gyre Therapeutics Inc insiders own 80.84% of total outstanding shares while institutional holders control 2.14%, with the float percentage being 11.16%. BLACKROCK INC. is the largest shareholder of the company, while 67.0 institutions own stock in it. As of 2024-06-30, the company held over 0.5 million shares (or 0.5842% of all shares), a total value of $5.96 million in shares.
The next largest institutional holding, with 0.26 million shares, is of GEODE CAPITAL MANAGEMENT, LLC’s that is approximately 0.3039% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.1 million.
